Sight Sciences raises 2025 revenue guidance to $76M-$78M while accelerating TearCare commercialization (NASDAQ:SGHT)
Sight Sciences(US:SGHT) Seeking Alphaยท2025-11-07 03:16Group 1 - The article does not provide any specific content or key points related to a company or industry [1]